id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-2349-0006,FDA,FDA-2014-E-2349,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-11-16T05:00:00Z,2016,11,2016-11-16T05:00:00Z,,2016-11-16T17:53:52Z,,0,0,0900006482399eec
FDA-2014-E-2349-0005,FDA,FDA-2014-E-2349,Determination of Regulatory Review Period for Purposes of Patent  Extension; OPSUMIT,Notice,Determinations,2016-03-10T05:00:00Z,2016,3,2016-03-10T05:00:00Z,2016-09-07T03:59:59Z,2016-03-10T15:02:46Z,2016-05389,0,0,0900006481eb7a77
FDA-2014-E-2349-0004,FDA,FDA-2014-E-2349,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-12-31T05:00:00Z,2015,12,2015-12-31T05:00:00Z,,2015-12-31T16:22:53Z,,0,0,0900006481ddf550
FDA-2014-E-2349-0003,FDA,FDA-2014-E-2349,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-05-12T04:00:00Z,2015,5,2015-05-12T04:00:00Z,,2015-05-12T14:14:42Z,,0,0,0900006481adb92f
FDA-2014-E-2349-0002,FDA,FDA-2014-E-2349,Patent Extension Application from Hoxic & Associates (on behalf of Actelion Pharmaceuticals Ltd),Other,Application,2015-02-26T05:00:00Z,2015,2,2015-02-26T05:00:00Z,,2015-02-26T20:16:56Z,,0,0,0900006481a1a63c
FDA-2014-E-2349-0001,FDA,FDA-2014-E-2349,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-02-26T05:00:00Z,2015,2,2015-02-26T05:00:00Z,,2015-02-26T20:16:46Z,,0,0,0900006481a1a63d